Entera Bio Names Dr. Rachel B Wagman as Clinical Advisor and Board Member

JERUSALEM, May 15, 2024 – Entera Bio Ltd. (NASDAQ: ENTX), a prominent company focusing on orally administered peptides and small therapeutic proteins, has announced the appointment of Dr. Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings over two decades of expertise in metabolic bone disease and women's health research and drug development to the company. She has played a pivotal role in advancing five therapeutic molecules, including teriparatide (Forteo®), denosumab (Prolia®), and romosozumab (Evenity®), from clinical development to market approval and lifecycle management.

Miranda Toledano, CEO of Entera, expressed excitement about Dr. Wagman's joining, stating, "Rachel's patient-centric approach and proven track record in progressing multiple major treatments through clinical development to registration, along with her specialization in the therapeutic areas we are targeting, provide a substantial advantage for expanding our oral peptide pipeline."

Dr. Wagman shared her enthusiasm, noting, "I am dedicated to bringing innovative treatments to patients with unmet medical needs. In osteoporosis, complacency is the primary hurdle to reducing fracture risk among patients. Identifying new solutions for these needs remains crucial. Entera's unique oral peptide delivery technology holds the promise of addressing several chronic metabolic disorders. I am thrilled to collaborate with Entera's talented team and support their work, which has the potential to significantly enhance patient care."

Dr. Wagman's extensive clinical leadership experience includes roles at Eli Lilly, Amgen, and Myovant Sciences. At Myovant Sciences, she served as Senior Vice President of Clinical Development, where she played a key role in integrating Myovant’s development portfolio into the newly established Sumitomo Pharma America. Her academic credentials include a BA from the University of Pennsylvania, an MD from Jefferson Medical College, an Internal Medicine residency at Thomas Jefferson University Hospital, and a postdoctoral fellowship in Endocrinology, Gerontology, and Metabolism at Stanford University School of Medicine. She is a Fellow of both the American College of Endocrinology and the American College of Physicians, with dual board certifications in Internal Medicine and Endocrinology, Diabetes, and Metabolism.

Entera Bio is a clinical-stage company dedicated to developing oral peptide or protein replacement therapies to address significant unmet medical needs, leveraging a proprietary technology platform (N-Tab™). The company’s pipeline consists of five distinct, first-in-class oral peptide programs expected to enter clinical stages (from Phase 1 to Phase 3) by 2025. Entera's leading product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density (BMD) and high-risk osteoporosis, with no prior fractures. EB613 has successfully met primary and secondary endpoints in a Phase 2 study, and Entera is preparing for a Phase 3 registrational study projected to start by January 2025.

Additionally, Entera is working on EB612, an oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism, and developing the first oral oxyntomodulin, a dual-targeted GLP1/glucagon peptide, in tablet form for obesity treatment. Moreover, the company is collaborating with OPKO Health to develop an oral GLP-2 peptide tablet as an injection-free alternative for patients with rare malabsorption conditions such as short bowel syndrome.

Entera Bio continues to innovate in the field of oral peptide delivery, aiming to revolutionize treatment options for chronic metabolic disorders and improve patient outcomes significantly.